These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28482400)

  • 1. [Opportunities and challenges for the treatment of chronic hepatitis C].
    Luo BF; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):161-163. PubMed ID: 28482400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic hepatitis C: achievement, challenge and strategy to eliminate as a public health threat].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):161-168. PubMed ID: 29804387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and strategies for viral hepatitis control in Korea.
    Sinn DH; Cho EJ; Kim JH; Kim DY; Kim YJ; Choi MS
    Clin Mol Hepatol; 2017 Sep; 23(3):189-195. PubMed ID: 28942620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Introduction of World Health Organization Strategies and the Technical Advisory Committee actions on viral hepatitis control and status of the elimination of viral hepatitis in China].
    Cui FQ; Wang FZ; Zheng H; Liang XF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Sep; 42(9):1523-1526. PubMed ID: 34814578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral hepatitis in 2021: The challenges remaining and how we should tackle them.
    Dunn R; Wetten A; McPherson S; Donnelly MC
    World J Gastroenterol; 2022 Jan; 28(1):76-95. PubMed ID: 35125820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Viral hepatitis--trends].
    Manciuc C; Dorobăţ C; Filip-Ciubotaru FM
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):327-31. PubMed ID: 20700962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Chen CJ
    Gut; 2018 Apr; 67(4):595-598. PubMed ID: 29367206
    [No Abstract]   [Full Text] [Related]  

  • 8. Viral hepatitis C in 2014--the beginning of the end?
    Prelipcean CC; Gogălniceanu P; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):272-8. PubMed ID: 25076687
    [No Abstract]   [Full Text] [Related]  

  • 9. Leaving behind pegylated interferon-based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by WHO.
    Lazarus JV; Pericàs JM; Elsharkawy AM
    Liver Int; 2018 Nov; 38(11):1902-1905. PubMed ID: 30358061
    [No Abstract]   [Full Text] [Related]  

  • 10. "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination.
    Lancaster K; Rhodes T; Rance J
    Int J Drug Policy; 2020 Jun; 80():102419. PubMed ID: 30975593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference.
    Hatzakis A; Van Damme P; Alcorn K; Gore C; Benazzouz M; Berkane S; Buti M; Carballo M; Cortes Martins H; Deuffic-Burban S; Dominguez A; Donoghoe M; Elzouki AN; Ben-Alaya Bouafif N; Esmat G; Esteban R; Fabri M; Fenton K; Goldberg D; Goulis I; Hadjichristodoulou C; Hatzigeorgiou T; Hamouda O; Hasurdjiev S; Hughes S; Kautz A; Malik M; Manolakopoulos S; Matičič M; Papatheodoridis G; Peck R; Peterle A; Potamitis G; Prati D; Roudot-Thoraval F; Reic T; Sharara A; Shennak M; Shiha G; Shouval D; Sočan M; Thomas H; Thursz M; Tosti M; Trépo C; Vince A; Vounou E; Wiessing L; Manns M
    J Viral Hepat; 2013 Aug; 20 Suppl 2():1-20. PubMed ID: 23827008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral hepatitis in the elderly.
    Carrion AF; Martin P
    Am J Gastroenterol; 2012 May; 107(5):691-7. PubMed ID: 22290404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is hepatitis virus resistance to antiviral drugs a threat?
    Pawlotsky JM
    Gastroenterology; 2012 May; 142(6):1369-72. PubMed ID: 22537445
    [No Abstract]   [Full Text] [Related]  

  • 14. [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E].
    Bartenschlager R; Cornberg M; Pietschmann T
    Internist (Berl); 2017 Jul; 58(7):666-674. PubMed ID: 28631044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
    Easterbrook P; Sands A; Harmanci H
    Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Elimination of hepatitis C, our progress, challenges and hopes].
    Rao HY; Li MY; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):809-811. PubMed ID: 33105921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiology of hepatitis C and vaccine perspectives].
    Nau JY
    Rev Med Suisse; 2016 Jan; 12(503):234-5. PubMed ID: 26939196
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic viral hepatitis as a public health issue in the world.
    Lavanchy D
    Best Pract Res Clin Gastroenterol; 2008; 22(6):991-1008. PubMed ID: 19187863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine.
    Stasi C; Silvestri C; Voller F; Cipriani F
    J Infect Public Health; 2016; 9(4):389-95. PubMed ID: 26148849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micro-elimination of hepatitis C virus infection in β-Thalassaemia major patients: Positively moving towards the World Health Organisation 2030 eradication goal.
    Giannini EG; Aghemo A
    Dig Liver Dis; 2019 Apr; 51(4):568-569. PubMed ID: 30691776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.